Humacyte, Inc. Other Income and Expense
Humacyte, Inc. (HUMA) reported Other Income and Expense of -$9.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-12
- Humacyte, Inc. nonoperating income (expense) for the quarter ending 2026-06-30 was -$9.81M.
- Humacyte, Inc. nonoperating income (expense) for the quarter ending 2026-03-31 was $11.32M, a 81.84% decline year-over-year.
- Humacyte, Inc. nonoperating income (expense) for the quarter ending 2025-12-31 was $6.03M, a 15.61% decline year-over-year.
- Humacyte, Inc. nonoperating income (expense) for the quarter ending 2025-09-30 was $6.88M.
- Humacyte, Inc. nonoperating income (expense) for fiscal 2025 was $67.30M.
- Humacyte, Inc. nonoperating income (expense) for fiscal 2024 was -$34.30M.
- Humacyte, Inc. nonoperating income (expense) for fiscal 2023 was -$10.73M, a 114.78% decline from fiscal 2022.
- Humacyte, Inc. nonoperating income (expense) for fiscal 2022 was $72.61M, a 32.67% increase from fiscal 2021.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 3 month as first filed | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 6 month as first filed | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.81M 10-Q · filed 2026-08-12 | $1.51M 10-Q · filed 2026-08-12 | $7.54M derived: sum of 3 quarters · filed 2026-08-12 | $14.42M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $11.32M 10-Q · filed 2026-05-13 | $17.35M derived: sum of 2 quarters · filed 2026-05-13 | $24.23M derived: sum of 3 quarters · filed 2026-05-13 | $16.30M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $12.91M derived: sum of 2 quarters · filed 2026-03-27 | $4.98M derived: sum of 3 quarters · filed 2026-08-12 | $67.30M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | $6.88M 10-Q · filed 2025-11-12 | -$1.05M derived: sum of 2 quarters · filed 2026-08-12 | $61.27M 10-Q · filed 2025-11-12 | $68.42M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | -$7.93M 10-Q · filed 2026-08-12 | $54.39M 10-Q · filed 2026-08-12 | $61.54M derived: sum of 3 quarters · filed 2026-08-12 | $52.57M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $62.32M 10-Q · filed 2026-05-13 | $69.47M derived: sum of 2 quarters · filed 2026-05-13 | $60.50M derived: sum of 3 quarters · filed 2026-05-13 | $33.34M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$1.82M derived: sum of 2 quarters · filed 2026-03-27 | -$28.98M derived: sum of 3 quarters · filed 2026-03-27 | -$34.30M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | -$8.97M 10-Q · filed 2025-11-12 | -$36.13M derived: sum of 2 quarters · filed 2025-11-12 | -$41.45M 10-Q · filed 2025-11-12 | -$40.38M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$27.16M 10-Q · filed 2025-08-11 | -$32.48M 10-Q · filed 2025-08-11 | -$31.41M derived: sum of 3 quarters · filed 2025-08-11 | -$32.78M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | -$5.32M 10-Q · filed 2025-05-13 | -$4.24M derived: sum of 2 quarters · filed 2025-05-13 | -$5.62M derived: sum of 3 quarters · filed 2025-05-13 | -$1.59M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$297.00K derived: sum of 2 quarters · filed 2025-03-31 | $3.73M derived: sum of 3 quarters · filed 2025-03-31 | -$10.73M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$1.37M 10-Q · filed 2024-11-08 | $2.65M derived: sum of 2 quarters · filed 2024-11-08 | -$11.80M 10-Q · filed 2024-11-08 | $5.26M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $4.03M 10-Q · filed 2024-08-13 | -$10.43M 10-Q · filed 2024-08-13 | $6.64M derived: sum of 3 quarters · filed 2024-08-13 | $4.85M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$14.46M 10-Q · filed 2024-05-13 | $2.61M derived: sum of 2 quarters · filed 2024-05-13 | $826.00K derived: sum of 3 quarters · filed 2024-05-13 | $56.23M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $17.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $15.28M derived: sum of 2 quarters · filed 2024-03-28 | $70.68M derived: sum of 3 quarters · filed 2024-03-28 | $72.61M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$1.79M 10-Q · filed 2023-11-09 | $53.61M derived: sum of 2 quarters · filed 2023-11-09 | $55.54M 10-Q · filed 2023-11-09 | $119.75M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $55.40M 10-Q · filed 2023-08-14 | $57.33M 10-Q · filed 2023-08-14 | $121.54M derived: sum of 3 quarters · filed 2023-08-14 | $110.52M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $1.93M 10-Q · filed 2023-05-12 | $66.14M derived: sum of 2 quarters · filed 2023-05-12 | $55.12M derived: sum of 3 quarters · filed 2023-05-12 | $57.19M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $64.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $53.19M derived: sum of 2 quarters · filed 2023-03-24 | $55.26M derived: sum of 3 quarters · filed 2023-03-24 | $54.73M 10-K · filed 2023-03-24 | ||
| 2021-09-30 | -$11.02M 10-Q · filed 2022-11-10 | -$8.95M derived: sum of 2 quarters · filed 2022-11-10 | -$9.48M 10-Q · filed 2022-11-10 | -$7.26M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $2.07M 10-Q · filed 2022-08-12 | $529.89K 10-Q · filed 2021-08-16 | $1.54M 10-Q · filed 2022-08-12 | -$8.41M 10-Q · filed 2021-08-16 | $3.76M derived: sum of 3 quarters · filed 2022-08-12 | $3.21M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$532.00K 10-Q · filed 2022-05-13 | -$8.94M 10-Q · filed 2021-05-17 | $1.68M derived: sum of 2 quarters · filed 2022-05-13 | $1.14M derived: sum of 3 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $2.22M derived: 10-K/A 6 month − 10-Q 3 month · filed 2021-05-14 | $1.67M 10-K/A · filed 2021-05-14 | $16.19K 10-K · filed 2021-02-16 | -$1.92M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | -$547.00K 10-Q · filed 2021-11-15 | -$22.18K 10-Q · filed 2020-11-13 | -$1.38M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |